Cite
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
MLA
Frances McSherry, et al. “Phase I/II Trial of Vorinostat, Bevacizumab, and Daily Temozolomide for Recurrent Malignant Gliomas.” Journal of Neuro-Oncology, vol. 137, Dec. 2017, pp. 349–56. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1450eb351b25d2f4430b3325661f5a42&authtype=sso&custid=ns315887.
APA
Frances McSherry, Annick Desjardins, Eric S. Lipp, David A. Reardon, James E. Herndon, Henry S. Friedman, Elizabeth Miller, & Katherine B. Peters. (2017). Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Journal of Neuro-Oncology, 137, 349–356.
Chicago
Frances McSherry, Annick Desjardins, Eric S. Lipp, David A. Reardon, James E. Herndon, Henry S. Friedman, Elizabeth Miller, and Katherine B. Peters. 2017. “Phase I/II Trial of Vorinostat, Bevacizumab, and Daily Temozolomide for Recurrent Malignant Gliomas.” Journal of Neuro-Oncology 137 (December): 349–56. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1450eb351b25d2f4430b3325661f5a42&authtype=sso&custid=ns315887.